Abstract Early detection of primary melanoma tumors is essential because there is no effective treatment for metastatic melanoma. Several linear and cyclic radiolabeled amelanocyte stimulating hormone (a-MSH) analogs have been proposed to target the melanocortin type 1 receptor (MC1R) overexpressed in melanoma. The compact structure of a rhenium-cyclized a-MSH analog (Re-CCMSH) significantly enhanced its in vivo tumor uptake and reten- + moiety. The 99m Tc(CO) 3 -labeled conjugates were obtained in high yield, high specific activity, and high radiochemical purity. The cyclic 99m Tc(CO) 3 -labeled conjugate presents a remarkable internalization (87.1% of receptor-bound tracer and 50.5% of total applied activity, after 6 h at 37°C) and cellular retention (only 24.7% released from the cells after 5 h) in murine melanoma B16F1 cells. A significant tumor uptake and retention was obtained in melanoma-bearing C57BL6 mice for the cyclic radioconjugate [9.26 ± 0.83 and 11.31 ± 1.83% ID/g at 1 and 4 h after injection, respectively]. The linear 99m Tc(CO) 3 -pz-peptide presented lower values for both cellular internalization and tumor uptake. Receptor blocking studies with the potent (Nle 4 ,DPhe 7 )-aMSH agonist demonstrated the specificity of the radioconjugates to MC1R (74.8 and 44.5% reduction of tumor uptake at 4 h after injection for cyclic and linear radioconjugates, respectively).
Abstract Early detection of primary melanoma tumors is essential because there is no effective treatment for metastatic melanoma. Several linear and cyclic radiolabeled amelanocyte stimulating hormone (a-MSH) analogs have been proposed to target the melanocortin type 1 receptor (MC1R) overexpressed in melanoma. The compact structure of a rhenium-cyclized a-MSH analog (Re-CCMSH) significantly enhanced its in vivo tumor uptake and retention. Melanotan II (MT-II), a cyclic lactam analog of a-MSH (Ac-Nle-cyclo[Asp-His-DPhe-Arg-Trp-Lys]-NH 2 ]), is a very potent and stable agonist peptide largely used in the characterization of melanocortin receptors. Taking advantage of the superior biological features associated with the MT-II cyclic peptide, we assessed the effect of lactambased cyclization on the tumor-seeking properties of a-MSH analogs by comparing the pharmacokinetics profile of the 99m Tc-labeled cyclic peptide bAla-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH 2 with that of the linear analog bAla-Nle-Asp-His-DPhe-Arg-Trp-Lys-NH 2 in melanomabearing mice. We have synthesized and coupled the linear and cyclic peptides to a bifunctional chelator containing a pyrazolyl-diamine backbone (pz) through the amino group of bAla, and the resulting pz-peptide conjugates were reacted with the fac-[ 99m Tc(CO) 3 ] + moiety. The 99m Tc(CO) 3 -labeled conjugates were obtained in high yield, high specific activity, and high radiochemical purity. The cyclic 99m Tc(CO) 3 -labeled conjugate presents a remarkable internalization (87.1% of receptor-bound tracer and 50.5% of total applied activity, after 6 h at 37°C) and cellular retention (only 24.7% released from the cells after 5 h) in murine melanoma B16F1 cells. A significant tumor uptake and retention was obtained in melanoma-bearing C57BL6 mice for the cyclic radioconjugate [9.26 ± 0.83 and 11.31 ± 1.83% ID/g at 1 and 4 h after injection, respectively]. The linear 99m Tc(CO) 3 -pz-peptide presented lower values for both cellular internalization and tumor uptake. Receptor blocking studies with the potent (Nle 4 ,DPhe 7 )-aMSH agonist demonstrated the specificity of the radioconjugates to MC1R (74.8 and 44.5% reduction of tumor uptake at 4 h after injection for cyclic and linear radioconjugates, respectively). 
Introduction
The incidence and mortality rates of cutaneous melanoma are still increasing in most western countries. Early detection of primary melanoma tumors is essential, since the current treatments do not enhance substantially patient survival once metastasis has occurred [1] . Fluoro-2-deoxyglucose ( 18 F-FDG), the most widely used positronemitter radiopharmaceutical, is limited in detecting melanoma tumors with small foci [2] , and some melanoma cells are undetectable with 18 F-FDG because they use substrates other than glucose as an energy source [3] . Therefore, development of new melanoma-specific radiopharmaceuticals for imaging or internal radiotherapy is a subject of great interest and intense research. It has been reported that most murine and human melanoma metastasis bear upregulated a-melanocyte stimulating hormone (a-MSH) receptors, namely, the melanocortin type 1 receptor (MC1R) [4] [5] [6] . Since radiopeptides have proven their superior usefulness as radioactive probes for cancer diagnosis and internal radiotherapy, a significant research effort has been directed to the development of radiolabeled a-MSH analogs for diagnosis and treatment of melanoma [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . The tridecapeptide a-MSH, the most potent naturally occurring melanotropic peptide and the most active peptide of MC1R [24] , has a short half-life in humans, as do many other endogenous peptides ( Table 1 ). The minimal sequence required for biological activity was determined by structure-bioactivity studies to be His-Phe-Arg-Trp, and the replacement of Met 4 and Phe 7 by Nle and DPhe, respectively, led to the more potent (Nle 4 ,DPhe 7 )-aMSH (NDP-MSH) analog (Table 1) , which is enzymatically stable and has a longer half-life [25] .
Introduction of a cyclic constraint in a lead peptide may restrict the flexibility and favor peptide-receptor interactions, and is an effective way of generating ligands with enhanced potency, receptor selectivity, and enzymatic stability [25] . The concept of side chain to side chain cyclization of melanocortin peptides has been successfully applied, namely, in the case of Ac-[Cys 4 11 ), which have shown higher tumor uptake and lower kidney accumulation, potentially interesting imaging probes for primary and pulmonary metastatic melanoma detection [11, 18] . These analogs were also labeled with therapeutic radionuclides ( 188 Re and 212 Pb) and their tumor uptake and therapeutic efficacy were evaluated in melanoma models [12, 13, 21, 22] . For PET imaging of melanoma the cyclic ReCCMSH(Arg 11 ) peptide was labeled with 64 Cu, using DOTA and a crossbridged cyclam (CBTE2A) as bifunctional chelators [15, 23] .
These results taken together showed that metal-based cyclization improves the biological behavior of the radiolabeled a-MSH analogs. Furthermore, the high MC1R affinity, stability, and prolonged activity of the cyclic MT-II agonist prompted us to explore the 99m Tc(CO) 3 -labeling and evaluation of the biological properties of an analog of MT-II, the cyclic peptide bAla-Nle-cyclo[Asp-His-DPheArg-Trp-Lys]-NH 2 , as well as the advantages of the lactam-based cyclization by comparison with the corresponding linear peptide.
Thus, in this paper, we report on the synthesis and characterization of the cyclic (pz-bAla-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH 2 ) and linear (pz-bAla-Nle-AspHis-D-Phe-Arg-Trp-Lys-NH 2 ) peptide conjugates, as well as on their radiolabeling with the fac-[ 99m Tc(CO) 3 ] + core, a quite versatile synthon for labeling different types of bioactive molecules, including peptides [20, [26] [27] [28] [29] [30] [31] [32] [33] [34] . The bifunctional chelating agent used for metal stabilization (pz) was a tridentate ligand containing a pyrazolyl-diamine backbone, which has been used with success in the radiolabeling of several other peptides, including the a-MSH analog [Ac-Nle 4 [20, [31] [32] [33] [34] . We also describe the in vitro/in vivo stability studies, internalization/externalization in B16F1 cells, and biodistribution in murine melanoma-bearing mice of the radiolabeled conjugates. The advantages of using 99m Tc(CO) 3 -labeled cyclic analogs over the corresponding linear analogs for melanoma targeting are discussed.
Materials and methods

Materials
NDP-MSH was purchased from Neosystem (Strasbourg, France). Bovine serum albumin (BSA) was purchased from Sigma. Dulbecco's modified Eagle's medium (DMEM) containing GlutaMax I, fetal bovine serum, penicillin/ streptomycin antibiotic solution, trypsin-EDTA, and phosphate-buffered saline (PBS) pH 7.2 were all from Gibco-Invitrogen (Alfagene, Lisbon).
Pyrazolyl-peptide conjugates: synthesis and characterization
The tert-butoxycarbonyl (Boc) protected pyrazolyl ligand (Me 2 pzN[(CH 2 ) 3 COOH]NH-Boc or Boc-pz) was prepared as previously described [31, 32] . The linear conjugate pzbAla-Nle-Asp-His-DPhe-Arg-Trp-Lys-NH 2 was prepared by 9-fluorenylmethoxycarbonyl (Fmoc)/t-Bu solid-phase peptide synthesis on a Rink amide resin using the appropriate N a -Fmoc-protected amino acids and O-(benzotriazol-1-yl)-N,N,N 0 ,N 0 -tetramethyluronium tetrafluoroborate (TBTU) as a coupling agent [35, 36] . Boc-pz was incorporated on-resin to the N-terminus after assembly of the amino acid sequence. The conjugate, pz-bAla-NleAsp-His-DPhe-Arg-Trp-Lys-NH 2 , was cleaved from the resin by acidolytic treatment with a cocktail having 95% trifluoroacetic acid (TFA) and appropriate scavengers (e.g., triethylsilane) to capture any reactive undesired species formed. The Boc group was also removed in the acidolysis.
The cyclic conjugate pz-bAla-Nle-cyclo[Asp-His-DPheArg-Trp-Lys]-NH 2 was also prepared by standard Fmoc/ t -Bu solid-phase peptide synthesis using the specially protected Fmoc-Asp(ODmab)-OH and Fmoc-Lys(ivDde)-OH amino acid derivatives in order to allow on-resin cyclization prior to cleavage and full deprotection of the final peptide [37] [38] [39] . Briefly, the linear peptide sequence was normally assembled on a Fmoc-Rink-MBHA resin (0.30 mmol/g) up until the incorporation of FmocAsp(ODmab)-OH, using TBTU as a coupling agent and 20% piperidine in dimethlyformamide for Fmoc-removal cycles [37] . Once Fmoc-Asp(ODmab) had been quantitatively incorporated in the peptidyl resin, this was treated with a freshly prepared mixture of hydroxylamine hydrochloride and imidazole in N-methylpyrrolidone to accomplish the selective and simultaneous removal of the ODmab and ivDde side chain protecting groups [40] (P. Gomes et al., unpublished results). Condensation of the Asp and Lys side chains to form the intramolecular lactam bridge was carried out using (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (6 equiv), diisopropylethylamine (12 equiv), and 1-hydroxybenzotriazole (6 equiv) [37] . After lactamization had reached completion, normal assembly of the remaining peptide chain was resumed up to the quantitative incorporation of the N-terminal Boc-pz ligand. Full deprotection and cleavage of the final peptide from the solid support was performed by treatment of the peptidyl resin with TFA containing 2.5% H 2 O and 2.5% triisopropylsilane. The crude product was purified by semipreparative reversedphase (RP) high-performance liquid chromatography (HPLC) (better than 97%) and successfully characterized as the target peptide by amino acid analysis and electrospray ionization mass spectrometry (ESI-MS was done according to a previously described procedure, using an Isolink Ò kit (Mallinckrodt) [31, 32] . In a nitrogenpurged glass vial, 100 lL of a 6 9 10 -4 M solution of the conjugate pz-aMSH analog was added to 900 lL of a solution of fac-[ 99m Tc(CO) 3 (H 2 O) 3 ] + (37-74 MBq) in PBS. The reaction mixture was incubated at 90 or 100°C for 50 or 60 min, for the cyclic and linear conjugates respectively, and then analyzed by RP-HPLC, using an analytical C-18 RP column. The radiolabeled compound was purified by semipreparative RP-HPLC. The activity corresponding to the 99m Tc(CO) 3 -conjugate was collected in a 50 mL Falcon flask containing 200 lL of PBS with 0.2% BSA or modified Eagle's medium (MEM) with 0.2% BSA, for biodistribution or internalization studies, respectively. The solutions were concentrated to a final volume of 200 lL under a nitrogen stream, and the product was checked by thin-layer chromatography and HPLC (see in vitro stability), to confirm its purity and stability after purification and evaporation.
HPLC analysis RP-HPLC was performed using a PerkinElmer system (LCPump, series 200) coupled to a UV-vis detector (LC 290, PerkinElmer or SDP-10AV, Shimadzu) and a c-detector (LB 507 or LB 509, Berthold) for the 99m Tc compounds. Analytical separations were achieved on a Hypersil ODS column (250 mm 9 4 mm, 10 lm). Semipreparative separations of the radioactive complexes were achieved on a Hypersil ODS column (250 mm 9 8 mm, 10 lm). The contents of the columns were eluted with a binary gradient system with a flow rate of 1.0 mL/min (analytical), 2.0 mL/ min (semipreparative for the linear radioconjugate) or 3.0 mL/min (semipreparative for the cyclic radioconjugate). Mobile phase A was 0.5% TFA and mobile phase B was CH 3 CN, 0.5% TFA. The method for the analytical control of the radioconjugates was as follows: 0-18 min, 15-100% mobile phase B; 18-20 min, 100-15% mobile phase B; 20-30 min, 15% mobile phase B. The method for semipreparative separation of the linear radioconjugate was as follows: 0-3 min, 0% mobile phase B; 3-3.1 min, 0-25% mobile phase B; 3.1-9 min, 25% mobile phase B; 9-9.1 min, 25-34% mobile phase B; 9. Thin-layer chromatography analysis Thin-layer chromatography (TLC) was performed using silica gel TLC strips (Polygram Sil G, Macherey-Nagel) developed with a mobile phase of 5% 6 N HCl in methanol. Radioactive distribution on the TLC strips was detected using a Berthold LB 505 detector coupled to a radiochromatogram scanner.
Partition coefficient
The lipophilicity of the radioconjugates was evaluated by the ''shakeflask'' method [41] . The radioconjugates were added to a mixture of octanol (1 mL) and 0.1 M PBS pH 7.4 (1 mL), previously saturated in each other by stirring the mixture (1 min). This mixture was vortexed and centrifuged (3,000 rpm, 10 min, room temperature) to allow phase separation. Aliquots of both octanol and PBS were counted using a c-counter. The partition coefficient (P o/w ) was calculated by dividing the counts in the octanol phase by those in the buffer, and the results were expressed as log P o/w .
In vitro stability
The in vitro stability of the radioconjugates was determined in fresh human plasma. The radioconjugates (100 lL, approximately 10 MBq) were added to fresh human plasma (1 mL), and the mixtures were incubated at 37°C. At appropriate time points (5 min, 45 min, and 4 h), 100 lL aliquots (in duplicate) were sampled and treated with 200 lL of ethanol to precipitate the proteins. Samples were centrifuged at 3,000 rpm for 15 min at 4°C. The supernatant was analyzed by HPLC. The stability of the radiolabeled conjugates in the solutions containing 0.2% BSA was checked by HPLC (column, Supelguard LC 3 DP 2 cm 9 4.6-mm inner diameter; eluents, A-10% 2-propanol and 90% 0.1% TFA, B-90% 2-propanol and 10% 0.1% TFA ; flux, 1 mL/min) and TLC (5% 6 N HCl/MeOH).
Cell culture B16F1 murine melanoma cells (ECACC, UK) were grown in DMEM containing GlutaMax I supplemented with 10% heat-inactivated fetal bovine serum and 1% penicillin/ streptomycin antibitiotic solution (all from Gibco, Alfagene, Lisbon). Cells were cultured in a humidified atmosphere of 95% air and 5% CO 2 at 37°C (Heraeus, Germany), with the medium changed every other day. The cells were adherent in monolayers and, when confluent, were harvested from the cell culture flasks with trypsin-EDTA (Gibco, Alfagene, Lisbon) and seeded farther apart.
Internalization and cellular retention studies
Internalization assays of the radioconjugates were performed in B16F1 murine melanoma cells seeded at a density of 0.2 million per well in 24-well tissue culture plates and allowed to attach overnight. The cells were incubated at room temperature or 37°C for a period of 5 min to 6 h with about 200,000 cpm of the conjugate in 0.5 mL of assay medium [MEM with 25 mM N-(2-hydroxyethyl)piperazine-N 0 -ethanesulfonic acid and 0.2% BSA]. Incubation was terminated by washing the cells with ice-cold assay medium. Cell-surface-bound radioligand was removed by two steps of acid wash (50 mM glycine, HCl/100 mM NaCl, pH 2.8) at room temperature for 5 min. The pH was neutralized with cold PBS with 0.2% BSA, and subsequently the cells were lysed by 10 min incubation with 1 N NaOH at 37°C to determine internalized radioligand. The cellular retention properties of the internalized radioconjugates were determined by incubating B16F1 cells with the radiolabeled compound for 3 h at 37°C, washing them with cold assay medium, removing the membrane-bound radioactivity with acid buffer wash, and monitoring radioactivity release into the culture media (0.5 mL) at 37°C. At different time points over a 5 h incubation period, the radioactivity in the medium and that in the cells were separately collected and counted.
Biodistribution
All animal experiments were performed in compliance with Portuguese regulations for animal treatment. The animals were housed in a temperature-and humidity-controlled room with a 12 h light/12 h dark schedule. Biodistribution of the radioconjugates was estimated in healthy and melanoma-bearing C57BL/6 female mice (8-10 weeks old). Mice were previously implanted subcutaneously with 1 9 10 6 B16F1 cells to generate a primary skin melanoma. Ten to 12 days after the inoculation, tumors reached a weight of 0.2-1 g.
Animals were intravenously injected into the retroorbital sinus with the radiolabeled complex (3-10 MBq) diluted in 100 lL of PBS pH 7.2. For confirming the specific uptake, 10 lg of NDP-MSH was coinjected with the radioactive complex. The effect of L-Lys coinjection on nonspecific kidney uptake of the peptide was examined in healthy C57BL/6 female mice. The animals were injected with a mixture of 3 MBq of cyclic labeled conjugate with 15 mg of L-Lys.
Mice were killed by cervical dislocation at 1, 4, and 24 h after injection. The dose administered and the radioactivity in the killed animals were measured using a dose calibrator (Curiemeter IGC-3, Aloka, Tokyo, Japan or Carpintec CRC-15W, Ramsey, USA). The difference between the radioactivity in the injected and that in the killed animals was assumed to be due to excretion. Tumors and normal tissues of interest were dissected, rinsed to remove excess blood, weighed, and their radioactivity was measured using a c-counter (LB2111, Berthold, Germany). The uptake in the tumor and healthy tissues of interest was calculated and expressed as a percentage of the injected radioactivity dose per gram of tissue. For blood, bone, muscle, and skin, total activity was estimated assuming that these organs constitute 6, 10, 40, and 15% of the total body weight, respectively. Urine was also collected and pooled together at the time the animals were killed.
In vivo stability
The stability of the complexes was assessed by urine, and murine serum RP-HPLC analysis, under identical conditions to those used for analyzing the original radiolabeled complexes. The samples were taken 1 h after injection. The urine collected at the time the mice were killed was filtered through a Millex GV filter (0.22 lm) before RP-HPLC analysis. Blood collected from the mice was centrifuged at 3,000 rpm for 15 min at 4°C, and the serum was separated. The serum was treated with ethanol in a 2:1 (v/v) ratio to precipitate the proteins. After centrifugation at 3,000 rpm for 15 min at 4°C, the supernatant was collected and analyzed by RP-HPLC.
Results and discussion
The presence of a-MSH receptors on melanoma cells and the fact that the receptors undergo rapid internalization on ligand binding have led researchers to explore the possibility of using radiolabeled a-MSH analogs for melanoma diagnosis or therapy. Encouraging data on the use of cyclic Re-CCMSH peptides and peptide labeling with the fac-[ 99m Tc(CO) 3 ] + moiety through the bifunctional chelating approach led us to consider the possibility of developing a new class of melanoma-specific 99m Tc(CO 3 )-labeled a-MSH analogs based on the MT-II peptide (Table 1) [25] . MT-II is a 23-membered ring formed from lactam cyclization through the Lys and Asp side chains. The bioactive conformation of MT-II involves a stable type 2 b-turn around the core His-DPhe-Arg-Trp region, compared with the type 3 b-turn of its linear analog, and the three hydrophobic aromatic rings in a stacked orientation opposite the hydrophilic side chain of Arg [25] . As a consequence, MT-II has a high affinity for melanocortin receptors.
Investigations on the effects of modifications at the Nterminal of MT-II and His-DPhe-Arg-Trp-NH 2 peptides on ligand potency [25] led us to believe that the affinity of MT-II for the MC1 receptor would not be negatively influenced by insertion of a bAla spacer and attachment of a pz chelator to the N-terminus, yielding the cyclic conjugate pz-bAla-Nle-cyclo[Asp-DPhe-Arg-Trp-Lys]-NH 2 (Scheme 1). To evaluate the advantages of lactam cyclization in the pharmacokinetic profile and tumor-targeting properties of the radioconjugates we also prepared and assessed the biological properties of the respective linear radioconjugate.
The cyclic and linear pz-peptide conjugates were prepared by standard solid-phase synthetic methods, purified by preparative RP-HPLC (purity 97% or better), and characterized by ESI-MS (m/z = 1,303 After optimization of the labeling conditions, namely, temperature and reaction time, radiochemical yields higher than 95% were obtained for both complexes using a final concentration of conjugate of 6 9 10 -5 M. The RP-HPLC analytical retention times were 11.7 and 10.8 min for the 99m Tc(CO) 3 -labeled cyclic and linear conjugates, respectively.
In order to increase specific activity and to maximize cellular and tumor uptake, the 99m Tc(CO) 3 -labeled conjugates were separated from the corresponding nonmetallated conjugates by semipreparative RP-HPLC. The fraction corresponding to each radioconjugate was collected in a 50 mL Falcon vial containing PBS or MEM solutions with 0.2% BSA (for biodistribution or internalization studies, respectively), to avoid adsorption phenomena, after evaporation of the HPLC elution solvent (CH 3 CN). The stability of the radioconjugates in PBS and MEM solutions was evaluated by HPLC and TLC, and it was found that no interaction with BSA and/or transmetallation took place under those conditions. Indeed, the HPLC chromatogram (Supelguard LC 3 DP 2 cm 9 4.6 mm inner diameter column) of the cyclic radioconjugate, after 4 h incubation at 37°C in a 0.2% BSA solution in PBS, displays only the radioconjugate (c-detection; retention time, 6.0 min) and BSA (UV detection; retention time, 9.8 min). Furthermore, on analyzing the TLC radiochromatogram of the cyclic radioconjugate after 24 h incubation at 37°C in a 0.2% BSA solution in MEM, we detected no hydrolyzed indicate that both the linear and the cyclic radiopeptide were stable in the presence of BSA and MEM, and confirm the high ability of the pyrazolyl-diamine chelator to stabilize the fac-[ 99m Tc(CO) 3 ] + moiety, avoiding transmetallation and/or reoxidation of the 99m Tc(I) [31] [32] [33] [34] . To assess the resistance of the radioconjugate to proteolytic degradation caused by endogenous peptidases and to predict its in vivo stability, we performed stability assays in fresh human plasma at 37°C. Analysis by RP-HPLC at different incubation time points (0 min, 5 min, 45 min, and 4 h) indicated high plasma stability with negligible degradation of both the linear and the cyclic radioconjugates, and a purity of 98% or better. Again, it has been shown that the pyrazolyl-diamine chelating unit is able to stabilize the metal center against transmetallation reactions to serumbased proteins.
The lipophilicity of both radiopeptides was evaluated by determination of the partition coefficient in physiological conditions. While the cyclic radioconjugate was moderately hydrophobic (log P o/w = 0.196 ± 0.003), the linear analog revealed a hydrophilic character (log P o/w = -1.074 ± 0.010).
The degree of internalization in B16F1 murine melanoma cells is a very important parameter for predicting tumor-targeting properties of the labeled peptides. Internalization studies performed for both radioconjugates, at room temperature and at 37°C, revealed that the cellular uptake was temperature-dependent and time-dependent (Fig. 1) .
As shown in Fig. 1 , higher levels of internalization were reached for the 99m Tc(CO) 3 -labeled cyclic conjugate, compared with the linear one. For instance, at 4 h after incubation (37°C), while only approximately 30% of the total cell-associated activity for the administered linear radioconjugate was taken up and internalized by the cells, 79% was internalized for the cyclic radiopeptide (Fig. 1,  panels A, B) . A striking difference between the levels of internalization is observed when this parameter is expressed as a percentage of total activity (Fig. 1, panel C) . In fact, while a negligible amount of radioactivity (1.6%) was internalized after 4 h for the linear radiopeptide, a remarkable internalization (41.8 and 50.5% for 4 and 6 h, respectively) was attained for the cyclic radioconjugate. These values are particularly high when compared with data previously reported for other radiolabeled a-MSH analogs. Indeed, for 64 Cu-DOTA-NAPamide and 99m Tc(CO) 3 -pz-NAPamide the maximum internalization observed was approximately 4.5% of the applied activity 3 h after incubation [9, 20] . In the case of the cyclic radiopeptide 99m Tc-CCMSH, using the same experimental conditions as those used for the 99m Tc(CO) 3 -labeled cyclic conjugate (0.2 9 10 6 melanoma B16F1 cells per well and 200,000 cpm of radioconjugate per well), the maximum internalization achieved was less than 4% [17] .
The cellular retention of the radioconjugates was also evaluated in B16F1 cells at different time points (Fig. 2) . A moderate retention was observed for the linear radioconjugate, with 35.3% of the cell-associated activity still remaining inside the cells after 4 h. In the case of the cyclic radioconjugate, a remarkably higher degree of cellular retention was observed. Indeed, the 99m Tc(CO) 3 -labeled cyclic conjugate was slowly released from the cells into the medium, with about 75% of the radioactivity still associated with the cells even after 5 h incubation. The enhanced internalization and intracellular retention of the cyclic radioconjugate, compared with that of its linear counterpart, is much likely related with the compact structure of the former. In fact, this structure seems to confer a more potent agonistic binding behavior to the peptide and an increased resistance to proteolysis. The biodistribution of 99m Tc(CO) 3 -labeled a-MSH analogs was examined in a B16F1 melanoma-bearing mouse model, at 1, 4, and 24 h after intravenous injection. Biodistribution data for the linear and the cyclic radioconjugate are presented in Tables 2 and 3, respectively. Biodistribution data from the linear radioconjugate indicate a fast clearance from the bloodstream [0.40 ± 0.05% injected dose (ID)/g, 4 h after injection] and other main organs, including skeletal and soft tissues like muscle. The overall radioactivity elimination occurs mainly by the urinary excretion route as indicated by the percentage of total excretion (56.4% at 1 h after injection), which predominantly corresponds to urine. Nevertheless, a significant portion of radioactivity is rapidly taken up by the liver and cleared into intestines, suggesting the importance of the hepatobiliary excretion pathway (11.7 ± 2.6 and 18.4 ± 3.1% ID per organ at 1 h after injection; 2.1 ± 0.8 and 26.8 ± 2.4% ID per organ at 4 h after injection, for liver and intestine, respectively).
The effect of cyclization on the biodistribution profile of the radioconjugate was mainly reflected in the decrease of clearance from most organs and in the radioactivity retained in the excretory organs, like liver and kidney. As a consequence of this behavior, the overall excretion from the whole animal body was significantly low. Indeed, 1 h after injection only 14.2% of the total activity was eliminated and 67% of that activity still remained in the animal 4 h after injection.
Owing to the high liver mass, the uptake for the cyclic analog in this organ was relatively high (23.5 ± 1.3% ID per organ, 4 h after injection), when compared with the kidney uptake (9.2 ± 0.7% ID per organ, 4 h after injection). Nevertheless, this result could be predicted from the lipophilic character (log P o/w = 0.196 ± 0.003) presented by the cyclic radioconjugate. A shift from the hepatobiliary 3 -labeled conjugates is related to tumor uptake. While a low tumor uptake for the 99m Tc-labeled linear peptide was found (1.96 ± 0.17 and 0.99 ± 0.08% ID/g at 1 and 4 h after injection, respectively), a fast and remarkable activity accumulation in the MC1R-expressing B16F1 tumor was observed for the cyclic radioconjugate. Indeed, 1 h after injection, a tumor uptake of 9.26 ± 0.83% ID/g was found, with this value increasing slowly to 11.31 ± 1.83% ID/g at 4 h after injection. The activity was then slowly washed out from the tumor, and the uptake dropped to a still relevant value of 3.48 ± 0.40% ID/g over 24 h. The high tumor uptake and the high tumor retention are in agreement with the high internalization and slow washout observed in in vitro studies with B16F1 cells for the cyclic radioconjugate, reflecting again the advantages of lactam cyclization in MC1R affinity and potency and in resistance to intracellular degradation.
The in vivo specificity of the radioconjugates for the MC1R was evaluated by their coadministration with cold NDP-MSH peptide (linear a-MSH peptide analog with picomolar affinity for the MC1R expressed on murine melanoma cells) in the same animal model. The receptorblocking studies at 4 h after injection revealed that the tumor uptake was significantly reduced by 74.8 and 44.5% for the cyclic and linear radioconjugates, respectively, in the presence of NDP-MSH, without significant changes in the biodistribution profile of the radioconjugates in healthy tissues (Tables 2, 3 ). These results confirmed that tumor uptake of both radioconjugates is MC1R-mediated, and that both peptides kept their biological activity upon conjugation to the pz-containing chelator and consequent 99m Tc(CO) 3 labeling. Tumor-to-blood and tumor-to-muscle uptake ratios were higher for the cyclic than for the linear radioconjugate despite the slow clearance from nontarget organs. Furthermore, for the cyclic radioconjugate the tumor-to-blood and tumor-to-muscle uptake ratios increased from 6.8 and 61.4 (4 h after injection) to 17.4 and 116 (24 h after injection), which also indicates a receptor-mediated transport, and subsequent intracellular trapping of this radiocomplex in the MC1R-expressing tumor.
The high tumor uptake and retention found for the 99m Tc(CO) 3 -labeled cyclic conjugate, compared with its linear counterpart, is in full agreement with the data obtained for the cyclic 99m Tc/Re-CCMSH analog, using the same animal model (B16F1 melanoma-bearing C57BL/6 mice) [10, 17] . The linear, nonmetallated, 111 In-DOTA- CCMSH exhibited also a lower tumor uptake than the homolog 111 In-DOTA-ReCCMSH (4.32 ± 0.59 vs. 9.49 ± 0.90% ID/g, 4 h after injection), clearly showing the benefit of ReO-mediated cyclization or peptide cyclization itself [10] . The best tumor uptake obtained with 111 In-DOTA-ReCCMSH (ReO cyclization) compared with the disulfide-bond-cyclized analog 111 In-DOTA-CMSH indicated that different methods of peptide cyclization yield molecules with different in vivo biodistribution properties [10] . In addition, 111 In-DOTA-ReCCMSH exhibited again superior tumor retention values compared with the cyclic 99m Tc-CCMSH at 24 h after injection (4.86 ± 1.52 vs. 1.38 ± 0.36% ID/g), although they were not statistically different at early time points [10, 17] . Herein, we have demonstrated that the cyclization through a lactam bridge appears to be another promising method of peptide cyclization for radiolabeled a-MSH analogs.
The 99m Tc(CO) 3 -labeled linear conjugate presents a very low tumor uptake (1.96 ± 0.17 and 0.99 ± 0.08% ID/ g at 1 and 4 h after injection, respectively). The same peptidic linear sequence, previously labeled with 111 In using the DOTA chelator, displayed also a relatively low tumor uptake without significant retention (4.31 ± 0.30 and 1.17 ± 0.13% ID/g for 4 and 24 h, respectively) [19] . These results taken together indicate that a constrained structure, conferred by lactam-based cyclization in this particular amino acid sequence, significantly favors the peptide-MC1R interaction.
However, cyclization of the linear peptide through lactam formation led to an impressive increase in kidney uptake (for the linear peptide 1.64 ± 0.19% ID/g and for the cyclic peptide 32.12 ± 0.19% ID/g, at 4 h after injection). Since it is well established that administration of cationic amino acids (Lys and Arg) inhibits renal accumulation of radiolabeled proteins and peptides [42, 43] , we performed a second set of biodistribution experiments in healthy mice in which Lys was coinjected with the cyclic radioconjugate (Table 4) . Interestingly, coadministration of this basic amino acid did not reduce significantly kidney accumulation of 99m Tc(CO) 3 -labeled cyclic peptide, which seems to indicate that the electrostatic interaction between the positively charged complex and the negatively charged surface of the proximal tubule cells is not a major factor for tubular reabsorption. This behavior has already been observed for similar a-MSH analogs labeled with other radiometals [M-DOTA-Re(Arg 11 )CCMSH; M is 90 Y, 177 Lu] [44] . In these studies, the multiligand megalin receptor, strongly expressed in the renal proximal tubule, was proposed as the main system involved in the renal uptake of the complexes [45, 46] .
In vivo stability studies revealed that both linear and cyclic radioconjugates are stable in blood (1 h after injection), as no metabolites could be detected (Fig. 3) .
The plasmatic protein-bound fraction for the radioconjugates was relatively low (21 and 22% for cyclic and linear radioconjugates, respectively). These results indicate again that metal complexation via the tridentate pyrazolyldiamine backbone overcomes potential binding/transmetallation to coordinating residues in circulating proteins, Fig. 3 Reversed-phase high-performance liquid chromatography chromatograms of the injected preparation, blood serum, and urine samples collected 1 h after injection such as His, Cys, or Met. In contrast, metabolites from both radioconjugates were found in urine. While a more hydrophobic species was observed for the linear radioconjugate (retention time 12.0 vs. 10.9 min), the metabolites of the cyclic radioconjugate were essentially hydrophilic species with the major metabolite appearing at 10.1 min.
In conclusion, we have prepared a MT-II-based cyclic 99m Tc(CO 3 ) radiopeptide and the corresponding linear analog in high yield and radiochemical purity. Both radioconjugates displayed good stability in vitro and in vivo. The cyclization through a lactam bridge resulted in a compact structure that remarkably enhanced the cellular internalization and retention, and consequently MC1R-mediated tumor uptake in B16F1 melanoma-bearing mice. Despite the promising tumor-targeting properties exhibited by the cyclic radiopeptide, its pharmacokinetic profile has still to be improved. Higher excretion and lower kidney uptake can certainly be reached either by modifying the physicochemical properties of the bifunctional chelating agent (e.g., charge and hydrophilicity) or by changing some of the amino acids of the peptide.
